Given that BTKi can cross the blood-brain barrier (BBB) and modulate both B cell and microglia/macrophage functions (9), it potentially allows direct manipulation of pathological drivers and mechanisms of MS within the CNS. Here, IBTK is linked to myeloid sarcoma.